These findings highlight that MYC level might be the predictive biomarker to identify cancers sensitive to TOP1 inhibitors.[71] We found a significant correlation between ETV4 expression and R‐loop‐induced DSBs in NSCLC cells upon CPT treatment. Here, MYC is linked to non-small cell lung carcinoma.